Prognostic value of ebv markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow‐up study

International Journal of Cancer

Volumn 42, Issue 2, 1988, Pages 176-181

  De Vathaire F ^a   Sancho Garner H ^a   De The H ^a   Pieddeloup, C ^a   Schwaab, G ^a   Ho, J H C ^b   Ellouz, R ^c   Micheau, C ^a   Cammoun, M ^c   Cachin, Y ^a   De The G ^d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

^c SALAH AZAIEZ INSTITUTE   (Tunisia)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIGEN;

EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; FRANCE; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGE FACTORS; ANTIBODIES, VIRAL; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGE; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR MARKERS, BIOLOGICAL;

EID: 0023809446     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910420206     Document Type: Article

References (17)

1. Regression models and life‐Tables (with discussion)
2. Epstein‐Barr virus‐Associated antibodies in Caucasian patients with carcinoma of the nasopharynx and in long‐Term survivors after treatment
3. Nasopharyngeal carcinoma. X. Presence of Epstein‐Barr genomes in epithelial cells of tumors from high‐ and medium‐Risk areas
4. Nasopharyngeal carcinoma (nPC). VI. Presence of an EBV nuclear antigen in fresh tumor biopsies: preliminary results
5. Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other EBV antigens in Chinese patients
6. Immunofluorescence in cells derived from Burkitt's lymphoma
7. Antibodies to Epstein‐Barr virus in nasopharyngeal carcinoma and other head and neck neoplasms and control groups
8. Differential reactivity of human serum with early antigens induced by Epstein‐Barr virus
9. Nasopharyngeal carcinoma. Significance of changes in Epstein‐Ban virus related antibody patterns following therapy
10. An epidemiologic and clinical study of nasopharyngeal carcinoma
11. Recommendations
12. Long‐Term follow‐Up of IgG and 1 A antibodies against viral capsid antigen of Epstein‐Barr virus in nasopharyngeal carcinoma
13. Evaluation of response‐Time data involving transient states: an illustration using heart‐Transplant data
14. IgA antibody, antibody‐Dependent‐Cellular cytotoxicity and prognosis in patients with nasopharyngeal carcinoma
15. Clinical evaluation of EBV serology in American patients with nasopharyngeal carcinoma: etiology and control
16. EBV‐DNA in biopsies of Burkitt's tumors and anaplastic carcinomas of the nasopharynx